Cargando…

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

BACKGROUND: The mean 5–6-month survival after failed standard chemotherapy for metastatic colorectal cancer (mCRC) necessitates more effective treatments for refractory mCRC. For untreated mCRC, S-1 + oral leucovorin (SL) therapy offers promising results without severe toxicity. The ML18147 trial de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Kazuhisa, Taniguchi, Hiroya, Komori, Azusa, Narita, Yukiya, Nitta, Sohei, Nomura, Motoo, Kadowaki, Shigenori, Takahari, Daisuke, Ura, Takashi, Andoh, Masashi, Muro, Kei, Mori, Keita, Igarashi, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550068/ https://www.ncbi.nlm.nih.gov/pubmed/26311588 http://dx.doi.org/10.1186/s12885-015-1606-1

Ejemplares similares

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature
por: Mitani, Seiichiro, et al.
Publicado: (2017)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
por: Honda, Kazunori, et al.
Publicado: (2017)

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study
por: Honda, Kazunori, et al.
Publicado: (2018)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer
por: Honda, Kazunori, et al.
Publicado: (2019)

Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
por: Kadowaki, Shigenori, et al.
Publicado: (2014)

Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
por: Mitani, Seiichiro, et al.
Publicado: (2016)

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study
por: Kondoh, Chihiro, et al.
Publicado: (2015)

Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center
por: Ando, Masashi, et al.
Publicado: (2023)

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma
por: Kadowaki, Shigenori, et al.
Publicado: (2013)

A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

Updated Immunotherapy for Gastric Cancer
por: Narita, Yukiya, et al.
Publicado: (2023)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
por: Naiki, Taku, et al.
Publicado: (2017)

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study
por: Motoo, Nagane, et al.
Publicado: (2019)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
por: Yokota, T, et al.
Publicado: (2011)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis
por: Mitani, Seiichiro, et al.
Publicado: (2019)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
por: Nozawa, Kazuki, et al.
Publicado: (2020)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
por: Liu, Xiu, et al.
Publicado: (2023)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin
por: Bilir, Cemil, et al.
Publicado: (2014)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
por: Shitara, Kohei, et al.
Publicado: (2010)

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
por: Defferrari, Carlotta, et al.
Publicado: (2012)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake
por: Ogata, Takatsugu, et al.
Publicado: (2020)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report
por: Shibutani, Masatsune, et al.
Publicado: (2018)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_qpheoq5ves7noa0en4sbbpcsu4